Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT01626885 Completed - Schizophrenia Clinical Trials

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.

NCT ID: NCT01626872 Completed - Schizophrenia Clinical Trials

Long-Term Study of MP-214 in Patients With Schizophrenia

Start date: September 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.

NCT ID: NCT01626859 Completed - Schizophrenia Clinical Trials

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.

NCT ID: NCT01626456 Completed - Schizophrenia Clinical Trials

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Start date: June 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.

NCT ID: NCT01625897 Completed - Schizophrenia Clinical Trials

A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia

Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.

NCT ID: NCT01625000 Completed - Schizophrenia Clinical Trials

Safety and Efficacy of MP-214 in Patients With Schizophrenia

Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.

NCT ID: NCT01623713 Completed - Schizophrenia Clinical Trials

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

NCT ID: NCT01622166 Completed - Schizophrenia Clinical Trials

Art Therapy in Acute Schizophrenia

KUSS
Start date: August 2011
Phase: N/A
Study type: Interventional

Randomised, controlled, single-blinded pilot study to assess the efficacy of psychodynamic art therapy in a sample of hospitalized, (sub)acutely psychotic patients with a diagnosis of schizophrenia compared to a group of patients receiving treatment as usual. *Main hypothesis: Art therapy has no impact on clinical symptoms and the course of remission compared to TAU. *Exploratory hypotheses: Art therapy has no influence on quality of life, mentalizing function, self-efficacy and neuroleptic dosage compared to TAU.

NCT ID: NCT01620086 Completed - Schizophrenia Clinical Trials

Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia

Start date: June 2012
Phase: N/A
Study type: Interventional

This study compares the efficacy of low and high frequency repetitive transcranial magnetic stimulation (rTMS) as a means of treating subjects with schizophrenia. Magnetic pulses delivered over the scalp cause brain activity. This activity has been shown to help decrease the intensity and frequency of auditory hallucinations (AH) in schizophrenia. The investigators will compare whether low or high frequencies work best. The investigators will also examine what changes occur in the brain that are related to improvement.

NCT ID: NCT01620060 Completed - Schizophrenia Clinical Trials

Lurasidone Pediatric Pharmacokinetics Study

Start date: June 2012
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric disorders.